Diabetic drug Avandia in trouble



The antidiabetic drug rosiglitazone is in big trouble as the decisions from major regulatory bodies were announced today. The European Medicines Agency (EMA) announced today that it is recommending … [Read more...]


It’s not all bad news for rosiglitazone



Remember the controversy about the diabetic drug rosiglitazone (market name Avandia)? Remember the issues surrounding the APPROACH Trial - Assessment on the Prevention of Progression by Rosiglitazone … [Read more...]